Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenanthroline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 3/20 | 0.89 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.89 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.89 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.89 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.56 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.56 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.56 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.47 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 5/20 | 0.89 |
| ▸ | CCR8 | P51685 | 5/20 | 0.89 |
| ▸ | LMNA | P02545 | 4/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.89 |
| ▸ | MMP2 | P08253 | 2/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.89 |
| ▸ | MAPT | P10636 | 2/20 | 0.89 |
| ▸ | HTT | P42858 | 2/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.89 |
| ▸ | GMNN | O75496 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenanthroline SCHEMBL30165588 | 1.00 | CCR1 (0.89) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL5461212 | 0.97 | CCR1 (0.84) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL28973442 | 0.97 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL30477083 | 0.97 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL28519994 | 0.97 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL44857 | 0.97 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL31040598 | 0.97 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL28662342 | 0.97 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL725644 | 0.97 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL27616640 | 0.97 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111384445-B | Electrolyte composition and metal ion battery comprising same | 财团法人工业技术研究院 | 2022-04-15 | — | — | CN | claimed |
| US-11283110-B2 | Electrolyte composition and metal-ion battery employing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2022-03-22 | — | — | US | claimed |
| CN-112798585-A | Color development tube for on-site determination of ferrous concentration in water and detection method | 中国地质调查局水文地质环境地质调查中心 | 2021-05-14 | — | — | CN | claimed |
| CN-111384445-A | Electrolyte composition and metal ion battery comprising same | 财团法人工业技术研究院 | 2020-07-07 | — | — | CN | claimed |
| US-20200212489-A1 | ELECTROLYTE COMPOSITION AND METAL-ION BATTERY EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-07-02 | — | — | US | claimed |
| US-20200131431-A1 | CHEMICAL ADDITIVES AND SURFACTANT COMBINATIONS FOR FAVORABLE WETTABILITY ALTERATION AND IMPROVED HYDROCARBON RECOVERY FACTORS | ALCHEMY SCIENCES INC (US) | 2020-04-30 | — | — | US | claimed |
| US-20190153569-A1 | ALUMINUM ALLOY AND METHOD FOR MANUFACTURING ALUMINUM ALLOY | SUMITOMO ELECTRIC INDUSTRIES, LTD. (JP) | 2019-05-23 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0892865-A1 | METHOD FOR BLEACHING OF LIGNOCELLULOSIC FIBERS | Jaschinski, Thomas (DE) | 1999-01-27 | — | — | EP | claimed |
| WO-1997039179-A1 | METHOD FOR BLEACHING OF LIGNOCELLULOSIC FIBERS | JASCHINSKI THOMAS (DE) | 1997-10-23 | — | — | WO | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | UNIV ARIZONA (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4628100-A2 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | Gregg, John Malcolm Hall (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-0335971-A1 | SUPPORTED HETEROPOLYCYCLIC COMPOUNDS IN THE SEPARATION AND REMOVAL OF LATE TRANSITION METALS | MACEDO, Pedro B. (US) | 1989-10-11 | — | — | EP | disclosed |
| EP-0335971-A4 | SUPPORTED HETEROPOLYCYCLIC COMPOUNDS IN THE SEPARATION AND REMOVAL OF LATE TRANSITION METALS. | MACEDO PEDRO B (US) | 1989-09-11 | — | — | EP | disclosed |
| WO-1989003434-A1 | SUPPORTED HETEROPOLYCYCLIC COMPOUNDS IN THE SEPARATION AND REMOVAL OF LATE TRANSITION METALS | MACEDO, PEDRO, B. (US) | 1989-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | DNMT3L, DNMT3A, DNMT1 | CCR5 2034/4885HSP90AA1 4476/4885MMP8 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.